These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


503 related items for PubMed ID: 25245990

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Emergence of clinical strains of Mycoplasma genitalium harbouring alterations in ParC associated with fluoroquinolone resistance.
    Shimada Y, Deguchi T, Nakane K, Masue T, Yasuda M, Yokoi S, Ito S, Nakano M, Ito S, Ishiko H.
    Int J Antimicrob Agents; 2010 Sep; 36(3):255-8. PubMed ID: 20580532
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Analysis of fluoroquinolone-resistance using MIC determination and homology modelling of ParC of contemporary Mycoplasma genitalium strains.
    Hamasuna R, Hanzawa H, Moritomo A, Matsumoto M, Aono H, Tomisaki I, Akasaka T, Fujimoto N, Jensen JS.
    J Infect Chemother; 2022 Mar; 28(3):377-383. PubMed ID: 34836778
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. In Vitro Activity of Sitafloxacin and Additional Newer Generation Fluoroquinolones Against Ciprofloxacin-Resistant Neisseria gonorrhoeae Isolates.
    Hamasuna R, Ohnishi M, Matsumoto M, Okumura R, Unemo M, Matsumoto T.
    Microb Drug Resist; 2018 Mar; 24(1):30-34. PubMed ID: 28581359
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Impact of mutations in DNA gyrase genes on quinolone resistance in Campylobacter jejuni.
    Changkwanyeun R, Yamaguchi T, Kongsoi S, Changkaew K, Yokoyama K, Kim H, Suthienkul O, Usui M, Tamura Y, Nakajima C, Suzuki Y.
    Drug Test Anal; 2016 Oct; 8(10):1071-1076. PubMed ID: 26857529
    [Abstract] [Full Text] [Related]

  • 15. Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones.
    Rafii F, Park M, Novak JS.
    Antimicrob Agents Chemother; 2005 Feb; 49(2):488-92. PubMed ID: 15673722
    [Abstract] [Full Text] [Related]

  • 16. Characterization of Campylobacter jejuni DNA gyrase as the target of quinolones.
    Changkwanyeun R, Usui M, Kongsoi S, Yokoyama K, Kim H, Suthienkul O, Changkaew K, Nakajima C, Tamura Y, Suzuki Y.
    J Infect Chemother; 2015 Aug; 21(8):604-9. PubMed ID: 26096494
    [Abstract] [Full Text] [Related]

  • 17. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
    Cheng J, Thanassi JA, Thoma CL, Bradbury BJ, Deshpande M, Pucci MJ.
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2445-53. PubMed ID: 17502409
    [Abstract] [Full Text] [Related]

  • 18. Macrolide and fluoroquinolone resistance-associated mutations in Mycoplasma genitalium in Johannesburg, South Africa, 2007-2014.
    Muller EE, Mahlangu MP, Lewis DA, Kularatne RS.
    BMC Infect Dis; 2019 Feb 13; 19(1):148. PubMed ID: 30760230
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effectiveness of sitafloxacin monotherapy for quinolone-resistant rectal and urogenital Mycoplasma genitalium infections: a prospective cohort study.
    Ando N, Mizushima D, Takano M, Mitobe M, Kobayashi K, Kubota H, Miyake H, Suzuki J, Sadamasu K, Aoki T, Watanabe K, Uemura H, Yanagawa Y, Gatanaga H, Oka S.
    J Antimicrob Chemother; 2023 Aug 02; 78(8):2070-2079. PubMed ID: 37376970
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 26.